NGM and Janssen strike diabetes agreement
This article was originally published in Scrip
Executive Summary
NGM Biopharmaceuticals, which develops treatments for cardio-metabolic diseases, has signed a worldwide agreement with Johnson & Johnson subsidiary, Janssen, to develop novel therapeutics for treating Type 2 diabetes and metabolic diseases.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.